Stockscreener 앱 받기
0.35
1.41%
-0.005
시장 영업 전:
.35
Reviva Pharmaceuticals Holdings Inc 주식(RVPH)의 최신 뉴스
Sentiment Watch: How sensitive is Reviva Pharmaceuticals Holdings Inc Equity Warrant to inflationEarnings Growth Report & Stepwise Trade Signal Guides - baoquankhu1.vn
Sectors Review: Will Reviva Pharmaceuticals Holdings Inc benefit from green energy policiesJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Aug Levels: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant stock a top pick in earnings season2025 Fundamental Recap & Low Drawdown Momentum Ideas - Bộ Nội Vụ
Breakouts Watch: How Reviva Pharmaceuticals Holdings Inc stock reacts to Fed rate cutsWeekly Stock Analysis & Community Consensus Trade Alerts - Bộ Nội Vụ
Profit Recap: Can Reviva Pharmaceuticals Holdings Inc Equity Warrant withstand a market correctionAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Reviva Pharmaceuticals Holdings (RVPH) Records 37% in 2026 So far - Finviz
Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026 - Yahoo Finance
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock deliver sustainable ROEQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock a top pick in earnings seasonJuly 2025 Weekly Recap & High Conviction Trade Alerts - Улправда
Aug Opening: How strong is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock revenue growth2025 Fundamental Recap & Long-Term Investment Growth Plans - Улправда
symbol__ Stock Quote Price and Forecast - CNN
How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefits from tech adoptionRate Cut & Entry and Exit Point Strategies - Улправда
Is Reviva Pharmaceuticals Holdings Inc. stock trading near support levels2025 Market Outlook & High Yield Equity Trading Tips - Улправда
How strong is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock revenue growth2025 Fundamental Recap & Long-Term Investment Growth Plans - Улправда
Will Tonix Pharmaceuticals Holding Corp. stock see insider buyingTrade Volume Report & Smart Allocation Stock Tips - Улправда
Reviva Pharmaceuticals Holdings, Inc. Announces Publication on Clinical Vocal Biomarker Data from the Recover Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia - marketscreener.com
Aug PreEarnings: How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefits from tech adoption2025 Macro Impact & Weekly Chart Analysis and Trade Guides - Улправда
Will Reviva Pharmaceuticals Holdings Inc. stock maintain dividend yield2025 Retail Activity & Daily Profit Maximizing Trade Tips - Улправда
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia - The Manila Times
Reviva Announces Publication on Clinical Vocal Biomarker - GlobeNewswire
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue dividend increases - Улправда
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendBlue Chip Stock Analysis & Free Long-Term Investment Planning - Улправда
Worth Investment Trading Company Limited Shows Risk Reward Favoring Upside - Early Times
Chardan Capital assumes coverage on Reviva Pharmaceuticals stock with Buy rating - Investing.com Canada
Volatility Watch: Will Reviva Pharmaceuticals Holdings Inc Equity Warrant stock attract ESG investorsJuly 2025 Chart Watch & Verified Stock Trade Ideas - Bộ Nội Vụ
Reviva Pharmaceuticals Holdings Inc Stock Analysis and ForecastMarket Timing Techniques & Explosive Trading Portfolio - earlytimes.in
Relief Rally in Veeram Securities Limited Stock Can It HoldVolatility Adjusted Trading & Download Our Free Trading Blueprint - earlytimes.in
What analysts say about Reviva Pharmaceuticals Holdings Inc stockBollinger Bands Signals & Try Our Free Strategy Builder Now - earlytimes.in
Technical Charts Suggest Momentum Shift in Sapphire Foods India LimitedEarnings Forecast Updates & Learn to Trade with Real-Time Feedback - earlytimes.in
Largest borrow rate increases among liquid names - TipRanks
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum - The Manila Times
Dow Gains 100 Points; US Durable Goods Orders Decline In October - Sahm
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025 - ts2.tech
Reviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
D Boral Capital maintains Reviva Pharmaceuticals Holdings (RVPH) buy recommendation - MSN
Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat
FDA recommends second phase 3 trial for Reviva’s schizophrenia drug By Investing.com - Investing.com Nigeria
Reviva considers a second phase III in schizophrenia - BioWorld MedTech
Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock: plunges 50% after FDA calls for second Phase 3 schizophrenia trial - parameter.io
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Did RVPH Stock Crash 50% Today? - Stocktwits
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial By Investing.com - Investing.com Nigeria
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial - Investing.com Nigeria
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga
Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Reviva plans second Phase 3 trial after FDA feedback - TipRanks
2.44%
0.16%
자본화:
|
볼륨(24시간):